In short
PF-07293893 is an investigational oral medicine being studied for heart failure with preserved ejection fraction (HFpEF), a form of heart failure where the heart pumps normally but cannot relax properly. One completed Phase 1 trial in 24 healthy adults has tested single ascending doses of PF-07293893 to assess safety and tolerability. No marketing authorisation is recorded for this substance in the trial data, and it remains an experimental treatment under investigation.
Key points
- PF-07293893 is an investigational substance studied in heart failure with preserved ejection fraction (HFpEF).
- The only registered trial is a Phase 1 study in 24 healthy adult participants.
- The trial is completed and was designed to test single ascending doses given by mouth.
- The main goal was to measure safety and tolerability, including adverse events, vital signs, and heart monitoring.
- PF-07293893 was given as an oral powder for inhalation (DPI) and as a crystalline oral form in different dose strengths.
- No marketing authorisation or approved use is recorded for PF-07293893 in these registry data.
What is PF-07293893?
PF-07293893 is an investigational medicine that has not received marketing authorisation and is not approved for routine clinical use. The substance is recorded in the European Union Clinical Trials Information System (CTIS) under the therapeutic area of cardiovascular diseases. In the registry, the active substance is described only by its development code PF-07293893, with no trade name or other names listed. The trial record does not state the chemical class or biological origin of the substance, so these details remain unknown from the available data.
How does PF-07293893 work?
The mechanism of action of PF-07293893 is not described in the clinical trial registry record or in the substance data. The trial was designed to evaluate how different doses are tolerated and how the medicine acts in the body, but the specific molecular target or biological pathway is not stated in the available sources. Without supplementary information, the way PF-07293893 might influence heart failure cannot be explained from these data.
Which conditions is PF-07293893 studied for?
- Heart failure with preserved ejection fraction (HFpEF) — a type of heart failure in which the heart muscle contracts normally but the heart cannot fill with blood properly because it is stiff. The registered trial lists HFpEF as the condition under investigation.
How is PF-07293893 given?
PF-07293893 is given by mouth. The trial tested two oral formulations: a dry powder for inhalation (DPI) at a strength of 1500 milligrams and a crystalline oral form at 500 milligrams. A separate 1500-milligram oral dose of PF-07293893 was also included, along with matching placebos for each formulation. The trial used single ascending doses, meaning participants received one dose at a time, with the dose increasing between different groups to assess tolerability.
What do the clinical trials show?
One clinical trial of PF-07293893 is registered in the CTIS database. The trial is a Phase 1 study that enrolled 24 healthy adult participants and is now completed. The study evaluated single ascending doses of PF-07293893 given orally. The primary outcome measured safety and tolerability through assessment of adverse events, clinical safety laboratory tests, vital signs, continuous cardiac monitoring, 12-lead electrocardiograms, physical examinations, and neurological examinations. Because this was a Phase 1 study in healthy volunteers, it did not measure effectiveness in patients with heart failure. No results are reported in the registry record.
What side effects are known?
The registry record for the completed Phase 1 trial does not report any side effects or adverse event data. The study was designed to collect safety information, including adverse events and laboratory abnormalities, but the results are not included in the trial record. No supplementary sources with side effect information were provided, so the known side effect profile of PF-07293893 cannot be described.